Ark, a Singaporean medical technology firm, has bagged $40 million in a Series A funding round.
The Series A was led by Venturecraft shareholders and joined by Gaorong Capital.
Ark plans to use the funding to scale multi-center clinical studies on early cancer detection.
In addition, the funds will be used to advance and inaugurate new blood tests for the early detection of high prevalence cancers like lung, breast and colon cancer and to stimulate Ark’s market extension plans.